B+
Bull case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
CRMD
CorMedixBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-18
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.3
Score
AI commentary
The August company release supports a favorable Q2 operating narrative, but no quantified immediate post-release price reaction or verified subsequent analyst revisions are available in the packet. The October 16 anchor of $7.26 is below the prior baseline's September 25 anchor of $7.85; that comparison alone does not establish why the price changed. Zero-valued sentiment, options, short-interest and employee fields indicate unavailable measurements, not neutral readings. Catalyst probabilities and price moves are judgmental scenarios. Low coverage and a negative deterministic prior warrant monitoring rather than a conviction upgrade.
RankAlpha Sentiment Codex - 2026-10-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventREZZAYO prophylaxis sNDA statusHigh impact
The August earnings exhibit targeted a Q3 2026 submission with Mundipharma. That target has passed; submission or FDA acceptance is not confirmed by the checked sources. The earlier company release gave a broader second-half target after positive Phase III topline results. The next substantive update could resolve the timing gap [#8-K-2026-08-13] [#SEC-8K-2026-08-13] [#PR-2026-04-27].
2026-12-31catalystDefenCath utilization at newly contracted dialysis operatorHigh impact
CorMedix said a new large dialysis operator had begun ordering and would start a Q3 pilot. Subsequent utilization and realized economics, rather than contract coverage alone, will test durability after $66.1 million of Q2 DefenCath sales, particularly in the post-TDAPA reimbursement environment [#SEC-8K-2026-08-13].
2027-06-30catalystPotential FDA action on REZZAYO indication expansionHigh impact
Management anticipated FDA action in H1 2027 only if the prophylaxis sNDA is submitted and accepted. Approval could expand the commercial portfolio, while the unconfirmed submission timetable makes that action window uncertain [#SEC-8K-2026-08-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-18 • Updated nightlySource: Internal modelMethodology